DDInter1400 DDInter122
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Pazopanib {u} (Compound) treats {v} (Disease) kidney cancer
Pazopanib {u} (Compound) binds {v} (Gene) PIP4K2C
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C8 Inhibitors
Pazopanib {u} (Compound) downregulates {v} (Gene) MEST
Pazopanib {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Pazopanib (Compound) treats kidney cancer (Disease)
Pazopanib (Compound) binds PIP4K2C (Gene)
Pazopanib (Compound) upregulates SRC (Gene)
Pazopanib (Compound) is included by Cytochrome P450 2C8 Inhibitors (Pharmacologic Class)
Pazopanib (Compound) downregulates MEST (Gene)
Pazopanib (Compound) causes Rhinorrhoea (Side Effect)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab